Loading
Pharma-Bio Serv, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by PLAZA ELIZABETH, was filed 31 Dec 2009.
Pharma-Bio Serv, Inc.: what insiders have been doing
Pharma-Bio Serv, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 24 October 2025 to 24 October 2026, the disclosure feed for Pharma-Bio Serv, Inc. logged 1 filing by 1 insider.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
There has been no open-market purchase by an insider of Pharma-Bio Serv, Inc. for at least a year.
Across the 282 companies tracked on its exchange, the median is 8 filings; at 1 filing, this issuer sits below that mark. The full history, which starts in 2006, counts 4 purchases against 19 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 October 2025 lists revenue at 9.0 m USD and net income at -100,463 USD.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
137
Thresholds
n/a
Buy Volume
€354,647
4 ops. · all time
Sell Volume
€801,818
19 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,408 of 26,289 companies
32.5
score / 100
Value29
Quality36
FCF yld-2.1%
Earn yld-1.0%
EV/EBITDA·
ROE2.2%
Gross mgn32%
Net mgn-1.1%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended October 2025 · cache
US$0.45
Analyst consensus
1 analysts0.00/5
US$1.55Target US$1.55(+244%)US$1.55
Income statement
RevenueUS$9M
Gross profitUS$2.9M32% margin
EBITDA-US$408.6k-5% margin
Net income-US$100.5k2.7% margin
Valuation
PER (trailing)45.0x
PER (forward)4.1x
P/Book1.0x
Beta0.73
Balance sheet & cash
Market capUS$10.3M
Total debtUS$28.8k
Free Cash Flow-US$221.5k
Profitability & ownership
ROE2.2%
ROA-0.8%
% insiders64.9%
% institutions0.0%
Last declaration on 22 July 2026
Declarations137 total
42,504 shares0Common StockSEC:0001654954-26-006801:0
1,132 shares0Common StockSEC:0001654954-24-000378:2
1,132 shares0Common StockSEC:0001654954-24-000378:3
14,340 shares@ US$1.068.7% of flowCommon StockSEC:0001654954-24-000382:1
18,868 shares@ US$1.0613.8% of flowCommon StockSEC:0001654954-24-000378:1
20,000 shares@ US$1.0041.4% of flowCommon StockSEC:0001654954-24-000378:0
20,000 shares@ US$0.7628.7% of flowCommon StockSEC:0001654954-24-000382:0
17,094 shares@ US$1.1711.9% of flowCommon StockSEC:0001654954-23-003749:1
20,000 shares@ US$0.769.0% of flowCommon StockSEC:0001654954-23-003749:2
12,991 shares@ US$1.179.0% of flowCommon StockSEC:0001654954-23-003749:3
17,094 shares@ US$1.1712.0% of flowCommon StockSEC:0001654954-23-003751:1
20,000 shares@ US$0.769.2% of flowCommon StockSEC:0001654954-23-003751:2
12,991 shares@ US$1.179.2% of flowCommon StockSEC:0001654954-23-003751:3
17,094 shares@ US$1.1711.5% of flowCommon StockSEC:0001654954-23-003753:1
20,000 shares@ US$1.0053.4% of flowCommon StockSEC:0001654954-23-003749:0
20,000 shares@ US$1.0053.4% of flowCommon StockSEC:0001654954-23-003751:0
20,000 shares@ US$1.0038.1% of flowCommon StockSEC:0001654954-23-003753:0
7,167 shares@ US$1.152.0% of flowCommon StockSEC:0001654954-23-002546:1
76,522 shares@ US$1.1512.9% of flowCommon StockSEC:0001654954-23-002543:1
8,325 shares@ US$0.991.2% of flowCommon StockSEC:0001654954-23-002543:2
7,167 shares@ US$1.151.2% of flowCommon StockSEC:0001654954-23-002543:3
8,325 shares@ US$0.99100.0% of flowCommon StockSEC:0001654954-23-002546:0
100,000 shares@ US$0.88100.0% of flowCommon StockSEC:0001654954-23-002543:0
13,165 shares@ US$0.797.4% of flowCommon StockSEC:0001654954-23-000303:1
6,835 shares0Common StockSEC:0001654954-23-000303:2
25 of 137 declarations
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv, Inc. (PBSV) is a U.S. small-cap company focused on regulatory compliance and life-sciences consulting services. The company was organized as a Delaware corporation on January 14, 2004, and is headquartered in Dorado, Puerto Rico. Its operating footprint spans Puerto Rico, the United States, Europe, and, to a lesser extent, Brazil. PBSV serves pharmaceutical, biotechnology, medical device, cosmetic, food, chemical, and allied-products companies, with services centered on regulatory affairs, quality systems, validation, project management, and technology transfer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001304161/000165495426000710/pbsv_10k.htm))
From an equity-market perspective, an important clarification is that PBSV is quoted on the OTCQB market, not on the NYSE or NASDAQ. That makes it a niche microcap followed by a narrower investor base, including market participants who monitor SEC filings and insider activity closely. The company’s business model is service-oriented rather than asset-heavy: it monetizes technical expertise, client relationships, and regulatory know-how instead of manufacturing capacity or patented drug assets. In that sense, PBSV should be viewed as a specialized professional-services provider within the healthcare and life-sciences ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1304161/000165495426000710/pbsv_10k.htm?utm_source=openai))
Read moreShow less
PBSV’s competitive position rests on domain specialization and long-standing customer relationships. The company states that it has well-established ties with major pharmaceutical, biotechnology, medical device, and chemical manufacturers in Puerto Rico and the United States, which can provide cross-border commercial access. Its consulting teams include engineering and life-science professionals, former quality assurance managers and directors, and other experienced specialists. That mix supports a broad service offering that can cover compliance readiness, validation work, documentation support, and transfer-of-technology projects—capabilities that are particularly valuable when clients are navigating FDA requirements and international regulatory standards. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001304161/000165495426000710/pbsv_10k.htm))
Recent disclosures suggest a business that remains small but operationally steady. For the quarter ended January 31, 2026, the company reported revenue of about $2.3 million, slightly lower year over year, while net income improved to $32,860. In its fiscal 2025 annual report, PBSV described a solid liquidity position and outlined investments in technology, including an AI-based dashboard intended to automate business-development opportunities and support recruitment and placement. The company also referenced a shareholder dividend and an ongoing effort to strengthen its service portfolio and operating structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1304161/000165495426002338/pbsv_ex991.htm?utm_source=openai))
For international equity investors, the key takeaway is that Pharma-Bio Serv is not a drug developer or a high-growth platform stock; it is a specialized compliance and technology-transfer consultant serving regulated industries across multiple geographies, with Puerto Rico as its operational hub and the United States as a core market. That makes the name relevant primarily as a niche services exposure to the broader life-sciences supply chain. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001304161/000165495426000710/pbsv_10k.htm))
